[Transcoronary ablation of septal hypertrophy (TASH): supersedes it the surgery (myectomy)?].
Kuhn
H
H
Medizinische Klinik II-Schwerpunkt Kardiologie, Städtische Kliniken Bielefeld, Akademisches Lehrkrankenhaus der Universität Münster. KUHN@sk-bielefeld.de
Gietzen
F
F
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000188:drug therapy / Q000601:surgery*; D017115:Catheter Ablation / Q000009:adverse effects; D018592:Cross-Over Studies; D017548:Echocardiography, Transesophageal; D006346:Heart Septum / Q000601:surgery*; D006801:Humans; D010138:Pacemaker, Artificial; D011183:Postoperative Complications / Q000209:etiology; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014665:Vasodilator Agents / Q000627:therapeutic use; D014700:Verapamil / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D011433:Propranolol; D014700:Verapamil